For generations, Alzheimer's disease announced itself only after the damage was already deep — confirmed through spinal taps and brain scans that came too late for much to be done. Now, a blood test born from decades of neuroscience research at Washington University has received FDA clearance, offering physicians a simple, accurate way to detect the disease's biological fingerprints before the full weight of cognitive decline arrives. The approval of PrecivityAD2 arrives precisely as the first drugs capable of slowing Alzheimer's progression reach patients — drugs that work best when given ear
FDA Clears Blood Test for Earlier Alzheimer's Detection
A blood test that can identify who has the pathology before symptoms become severe opens a window for intervention that didn't exist before.
Mark
Why does it matter that this test uses mass spectrometry instead of the immunoassay methods other blood tests use?
Mimi
Mass spectrometry gives you quantitative measurements—exact numbers—rather than just a yes or no. It's the difference between knowing someone has amyloid and knowing how much amyloid they have. That precision matters when you're trying to match the accuracy of a spinal tap.
Mark
So before this test, if someone was worried about Alzheimer's, what would the doctor actually do?
Mimi
They'd start with cognitive testing, maybe an MRI to rule out other things. If they suspected Alzheimer's, they'd either do a spinal tap—which is invasive and uncomfortable—or a PET scan, which is expensive and exposes you to radiation. A blood test changes that completely.
Mark
The source mentions that these new Alzheimer's drugs are more effective when started sooner. How much sooner are we talking about?
Mimi
That's the thing we don't fully know yet. But the principle is clear: once neurodegeneration starts, it's harder to stop. If you can catch amyloid pathology before symptoms become severe, you have a better chance of slowing the decline. The test makes that possible.
Mark
What happens now that the FDA has cleared it? Does every doctor start ordering it tomorrow?
Mimi
No. Clearance is necessary but not sufficient. Insurance coverage is the real gate. A test that costs money but isn't covered won't get ordered much. The clearance makes coverage more likely, but that's still a separate negotiation.
Mark
The company is expanding in St. Louis. Is this a local story or a national one?
Mimi
Both. It's a local story about a university startup scaling up. But the national story is that early detection of Alzheimer's just became simpler and more accessible. That changes how millions of people might be diagnosed.
O Pulso
- Alzheimer's has long resisted early detection, forcing patients and families to wait for decline to become undeniable before a diagnosis could be confirmed through invasive and costly procedures.
- PrecivityAD2 uses high-resolution mass spectrometry to measure amyloid and tau proteins in a blood sample, matching the accuracy of spinal fluid tests at over 90% — even in patients with only mild symptoms.
- FDA clearance transforms the test from a specialty option into a broadly marketable clinical tool, unlocking the insurance coverage that determines whether most patients can actually access it.
- The approval lands at a pivotal moment: newly approved drugs can slow Alzheimer's progression, but their effectiveness depends on early intervention — making this diagnostic window a genuine turning point in care.
- C2N Diagnostics, the Washington University spinout behind the test, is expanding its St. Louis headquarters, signaling that blood-based Alzheimer's diagnostics are moving from research promise to clinical reality.
For generations, Alzheimer's disease announced itself only after the damage was already deep — confirmed through spinal taps and brain scans that came too late for much to be done. Now, a blood test born from decades of neuroscience research at Washington University has received FDA clearance, offering physicians a simple, accurate way to detect the disease's biological fingerprints before the full weight of cognitive decline arrives. The approval of PrecivityAD2 arrives precisely as the first drugs capable of slowing Alzheimer's progression reach patients — drugs that work best when given early — making the timing of this diagnostic advance as meaningful as the science behind it.
A blood test developed at Washington University School of Medicine has received FDA clearance, reshaping how physicians might detect Alzheimer's disease before it progresses beyond reach. The test, PrecivityAD2, was created by C2N Diagnostics — a company founded by WashU neuroscientists Randall Bateman and David Holtzman — and it identifies the amyloid plaques associated with Alzheimer's through a simple blood draw rather than a spinal tap or brain scan.
The science behind it is precise: instead of the immunoassay methods used by other blood tests, PrecivityAD2 employs high-resolution mass spectrometry to measure two forms of amyloid beta and two forms of tau — the protein biomarkers that mark Alzheimer's pathology. In clinical studies, it detected amyloid plaques with more than 90% accuracy, performing on par with far more invasive diagnostic methods, even in patients experiencing only mild cognitive symptoms.
The clearance arrives at a consequential moment. For decades, physicians could offer Alzheimer's patients little beyond symptom management. Now, the first drugs capable of actually slowing the disease's progression have reached patients — and they work best when administered early. A blood test that can identify pathology before symptoms become severe opens an intervention window that previously did not exist.
Beyond scientific validation, FDA clearance carries practical weight. It allows PrecivityAD2 to be marketed broadly to health systems that use federal approval as their quality standard, and — critically — it opens the path to insurance coverage. A test that patients cannot afford is a test that changes nothing. Coverage changes that calculation entirely.
Bateman and Holtzman built the scientific foundation for this work over many years, pioneering methods for measuring Alzheimer's biomarkers in cerebrospinal fluid and blood before co-founding C2N in 2007. The company now employs more than 120 people and is expanding into St. Louis' Cortex Innovation District. What this moment represents, beyond any single test, is a shift in the timeline of Alzheimer's care — one where diagnosis arrives early enough for medicine to matter.
A blood test developed at Washington University School of Medicine has just cleared the FDA, marking a shift in how doctors might catch Alzheimer's disease before it progresses too far. The test, called PrecivityAD2, was created by C2N Diagnostics, a startup born from the university's neurology labs, and it does something that matters: it finds the amyloid plaques associated with Alzheimer's using only a needle stick, not a spinal tap or a brain scan.
The technology behind it is elegant in its precision. Rather than relying on the immunoassay methods other blood tests use, PrecivityAD2 employs high-resolution mass spectrometry to measure specific proteins in the blood—amyloid beta in two forms, and tau in two forms. These biomarkers are the fingerprints of Alzheimer's pathology. In clinical studies, the test detected amyloid plaques with more than 90% accuracy, performing as well as the more invasive methods doctors have relied on for years, even in patients showing only mild cognitive symptoms.
The timing of this clearance matters because the landscape of Alzheimer's treatment has shifted. For decades, there was nothing to offer patients but management of symptoms. Now, the first drugs capable of actually slowing the disease's progression have reached patients, and they work best when started early. A blood test that can identify who has the pathology before symptoms become severe opens a window for intervention that didn't exist before. Randall Bateman, one of the neuroscientists who developed the underlying technology at WashU, put it plainly: with faster diagnosis, patients can receive earlier treatment, when treatments are most effective.
The FDA clearance itself is a formal validation that PrecivityAD2 has undergone rigorous evaluation and meets standards for accuracy and reliability. Before this, physicians could order the test for patients with mild cognitive symptoms, but the clearance allows it to be marketed more broadly to clinicians and health systems that use FDA approval as their quality benchmark. More importantly, it opens the door to insurance coverage. A test that costs money but isn't covered is a test many people won't get. Coverage changes that calculation.
The test grew out of foundational research by Bateman and David Holtzman, another distinguished neurology professor at WashU. They pioneered methods for measuring amyloid-beta and tau in cerebrospinal fluid and blood, work that established the scientific foundation for blood-based biomarker testing. When they co-founded C2N in 2007, they were betting that this research could be turned into something clinicians could actually use. The company now employs more than 120 researchers, physicians, and other professionals and is expanding its headquarters into St. Louis' Cortex Innovation District.
What makes this moment significant is not just the test itself, but what it represents about the future of Alzheimer's diagnosis. For years, identifying the disease meant waiting for cognitive decline to become obvious, then confirming it through expensive and invasive procedures. A simple blood test that can detect the underlying pathology before symptoms fully emerge changes the equation. It means more people could learn they have amyloid plaques in their brains while there's still time to intervene. It means the window for treatment widens. As new drugs move through the pipeline—and several promising candidates are in development—the ability to identify who needs them early becomes the critical piece of the puzzle.
Citações Notáveis
With FDA clearance, this innovation can reach more patients, increasing early and accurate diagnoses for people who are seeking causes of cognitive symptoms such as memory loss.— Randall Bateman, co-developer of the test
Achieving FDA clearance of the PrecivityAD2 blood test is a key milestone in our mission to transform the diagnosis and management of Alzheimer's disease on a path toward finding a cure.— David Holtzman, co-developer of the test
Quer a matéria completa?
Leia o original em News-Medical ↗
Health & Medicine